CN114990057B - Method for separating and culturing intramuscular fat cells of buffalo fetuses and inducing differentiation into fat - Google Patents
Method for separating and culturing intramuscular fat cells of buffalo fetuses and inducing differentiation into fat Download PDFInfo
- Publication number
- CN114990057B CN114990057B CN202210697735.9A CN202210697735A CN114990057B CN 114990057 B CN114990057 B CN 114990057B CN 202210697735 A CN202210697735 A CN 202210697735A CN 114990057 B CN114990057 B CN 114990057B
- Authority
- CN
- China
- Prior art keywords
- buffalo
- cells
- streptomycin
- culture medium
- intramuscular fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000007918 intramuscular administration Methods 0.000 title claims abstract description 48
- 210000001789 adipocyte Anatomy 0.000 title claims abstract description 41
- 230000004069 differentiation Effects 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 title claims abstract description 30
- 238000012258 culturing Methods 0.000 title claims abstract description 20
- 210000003754 fetus Anatomy 0.000 title claims abstract description 18
- 230000001939 inductive effect Effects 0.000 title claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims abstract description 76
- 230000006698 induction Effects 0.000 claims abstract description 38
- 239000002609 medium Substances 0.000 claims abstract description 36
- 239000001963 growth medium Substances 0.000 claims abstract description 29
- 241000283690 Bos taurus Species 0.000 claims abstract description 27
- 210000001519 tissue Anatomy 0.000 claims abstract description 27
- 238000012423 maintenance Methods 0.000 claims abstract description 23
- 230000029087 digestion Effects 0.000 claims abstract description 19
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 17
- 210000003205 muscle Anatomy 0.000 claims abstract description 17
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 claims abstract description 13
- 239000006228 supernatant Substances 0.000 claims abstract description 6
- 239000008188 pellet Substances 0.000 claims abstract description 5
- 230000001954 sterilising effect Effects 0.000 claims abstract description 3
- 238000004140 cleaning Methods 0.000 claims abstract 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 60
- 229960005322 streptomycin Drugs 0.000 claims description 30
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 20
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 20
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 18
- 239000008055 phosphate buffer solution Substances 0.000 claims description 18
- 230000002293 adipogenic effect Effects 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 239000012091 fetal bovine serum Substances 0.000 claims description 14
- 239000008363 phosphate buffer Substances 0.000 claims description 14
- 239000012266 salt solution Substances 0.000 claims description 13
- 210000001142 back Anatomy 0.000 claims description 10
- 102000004877 Insulin Human genes 0.000 claims description 9
- 108090001061 Insulin Proteins 0.000 claims description 9
- 210000002615 epidermis Anatomy 0.000 claims description 9
- 229940125396 insulin Drugs 0.000 claims description 9
- 229960004586 rosiglitazone Drugs 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 claims description 6
- 235000015278 beef Nutrition 0.000 claims description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 6
- 229960003957 dexamethasone Drugs 0.000 claims description 6
- 229930182555 Penicillin Natural products 0.000 claims description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 5
- 229940049954 penicillin Drugs 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 230000001464 adherent effect Effects 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 230000011218 segmentation Effects 0.000 claims description 4
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 244000309466 calf Species 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 6
- 230000009815 adipogenic differentiation Effects 0.000 abstract description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 17
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 14
- 230000001605 fetal effect Effects 0.000 description 9
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 239000006166 lysate Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 230000030944 contact inhibition Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- 101710186200 CCAAT/enhancer-binding protein Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101100226596 Gallus gallus FABP gene Proteins 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000011759 adipose tissue development Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- YNCMLFHHXWETLD-UHFFFAOYSA-N pyocyanin Chemical compound CN1C2=CC=CC=C2N=C2C1=CC=CC2=O YNCMLFHHXWETLD-UHFFFAOYSA-N 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 description 1
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 1
- 108050003772 Fatty acid-binding protein 4 Proteins 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 1
- 235000002294 Ilex volkensiana Nutrition 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 108091022862 fatty acid binding Proteins 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0653—Adipocytes; Adipose tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides, bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention relates to the field of cell engineering and tissue engineering, in particular to a method for separating and culturing intramuscular fat cells of buffalo fetuses and inducing differentiation into fat. The method comprises the following steps: taking the longus muscle of the buffalo embryo cattle back, and cleaning and sterilizing; dividing the longissimus tissue of buffalo embryo and cattle back; adding 0.2% collagenase I for digestion; adding complete medium to stop digestion; centrifuging the cells which terminate digestion, and discarding the supernatant to obtain a cell pellet; purifying cells by differential adherence; culturing the purified cells in an incubator with 5% CO 2 at 37 ℃ for 2 days, and changing the complete culture medium once; after the cell density reaches about 80%, the induction medium is replaced, the maintenance medium is replaced after the induction is carried out for 2 days, and then the maintenance medium is replaced every 2 days. The intramuscular fat cells obtained by the buffalo fetus obtained by the method have higher activity and capacity of adipogenic differentiation.
Description
Technical Field
The invention relates to the field of cell engineering and tissue engineering, in particular to a method for separating and culturing intramuscular fat cells of buffalo fetuses and adipogenic induced differentiation of the same.
Background
The current research shows that the nutrition value of buffalo meat is no more than that of yellow beef. Secondly, the current beef supply is not in demand. Therefore, the method has important significance for fully utilizing rich buffalo resources to relieve the supply and demand pressure of domestic beef. The flavor, taste and juiciness of buffalo are seriously affected by poor intramuscular deposition capability, so that the improvement of intramuscular fat deposition capability of buffalo is a problem to be solved. The buffalo fetal intramuscular fat cells are separated in vitro, cultured, induced and differentiated, and the buffalo intramuscular fat deposition is simulated in vitro, so that a referential meaning is provided for improving the meat quality of buffalo and analyzing the molecular mechanism of buffalo intramuscular fat deposition.
No technology for in vitro culture, induction and research of intramuscular adipocyte cells of other animals in fetal period and the technology for inducing adipogenesis is reported.
The invention patent application with the application publication number of CN109679898A discloses an improved method for inducing bovine intramuscular fat cells to perform adipogenic differentiation, which comprises the steps of culturing bovine intramuscular fat cells in DMEM/F12 culture medium containing 10% fetal bovine serum, and adding an induced differentiation agent for 2 days after the confluence of the bovine intramuscular fat cells reaches 100%. The composition of the induced differentiation agent is as follows: 3-isobutyl-1-methylxanthine: 0.5mM, dexamethasone: 1 μm, insulin: 10 μg/mL, rosebeliazone: 2. Mu. Mol/L.
Disclosure of Invention
The invention aims to provide a method for obtaining intramuscular fat cells of buffalo with better activity for isolated culture and induced adipogenic differentiation, and the obtained intramuscular fat cells have higher adipogenic differentiation capability.
The aim of the invention is achieved by the following technical scheme:
a method for separating, culturing and adipogenic inducing differentiation of buffalo fetal intramuscular fat cells comprises the following steps:
Step 1: and (3) disinfection: firstly, the epidermis of the buffalo embryo cattle is cleaned, the epidermis is removed, the longus muscle of the cattle dorsum of the buffalo embryo is taken, and the longus muscle tissue of the cattle dorsum is disinfected under the aseptic condition. Intramuscular fat content is one of the key indicators for evaluating beef quality, and the measurement criteria for intramuscular fat content (i.e., the level of intramuscular fat deposition) are: the longissimus dorsi cross section was taken and compared with a comparison card, or the longissimus dorsi was taken and the crude fat content was determined. Thus, the invention also uses the longus muscle of the back of the cow as a material to isolate intramuscular fat cells.
Specifically, the washing is to wash the buffalo embryo cattle skin by using 3 times of blue/streptomycin phosphate buffer salt solution, remove the skin and take the longus muscle of the buffalo embryo cattle back. The phosphate buffer salt solution of 3 times of penicillin/streptomycin is phosphate buffer salt solution added with 3 percent of penicillin/streptomycin, and the blue/streptomycin solution is a mixed solution prepared by 100U/mL penicillin and 0.1mg/mL streptomycin.
The sterilization is to soak the longissimus dorsum tissue of the cattle in sequence for 2 minutes by using a phosphate buffer solution which contains 1 percent, 2 percent and 3 percent of blue/chain mycin which is preheated under the aseptic condition, soak the longissimus dorsum tissue in 75 percent of alcohol for 30 seconds, and soak the longissimus dorsum tissue in sequence for 2 minutes by using the phosphate buffer solution which contains 3 percent, 2 percent and 1 percent of blue/chain mycin which is preheated.
Step 2: segmentation: dividing the longest muscle tissue blocks of the beef dorsum of the disinfected buffalo embryo; specifically, the sterilized longissimus muscle tissue blocks of buffalo embryo and cattle back can be divided into 1-2 mm 3 by scissors.
Step 3: digestion: the divided tissue pieces were digested by adding 0.2% collagenase I. Specifically, 1-2 mm 3 tissue blocks are transferred into a 15mL centrifuge tube by using a 1mL pipette, 0.2% collagenase I which is 2 times of the volume of the tissue blocks is added, and the tissue blocks are digested for 90-120 min on a constant temperature shaking table at 37 ℃ until flocculence appears.
Step 4: and (3) screening: adding complete culture medium to the digested tissue to terminate digestion; specifically, digestion was terminated by adding DMEM medium containing 20% fetal bovine serum and 1% diabody to the digested tissue in an equivalent volume of 0.2% collagenase I.
Step 5: and (3) centrifuging: centrifuging the cells which terminate digestion, and discarding the supernatant to obtain a cell pellet; specifically, the cells which have stopped digestion are transferred to a 50mL centrifuge tube through a 200 mesh cell sieve, and centrifuged at 1500rpm for 10min.
Step 6: purifying: the centrifuged cells are resuspended in DMEM medium containing 20% fetal calf serum and 1% diabody, and the cells are purified by differential adherence;
The differential adherence method comprises the following steps: culturing cells in an incubator at 37deg.C and 5% CO 2 for 1 hr, discarding culture medium containing non-adherent cells, washing with 1 times of blue/streptomycin phosphate buffer solution for 2 times, and adding DMEM culture medium containing 20% foetal calf serum and 1% double antibody into the cells; the phosphate buffer solution of 1 times of blue/streptomycin is phosphate buffer solution added with 1% of blue/streptomycin.
Step 7: culturing: the purified cells were cultured in an incubator at 37℃with 5% CO 2, and the DMEM medium containing 20% fetal bovine serum and 1% diabody was changed every 2 days. After the cell density reaches about 80%, the induction culture medium is replaced, the maintenance culture medium is replaced after the induction is carried out for 2 days, and then the maintenance culture medium is replaced every two days for 6-8 days.
The components of the induced differentiation agent in the induction medium are as follows: 0.5mM 3-isobutyl-1-methylxanthine, 1. Mu.M dexamethasone, 10. Mu.g/mL insulin and 1. Mu.M rosiglitazone; the components of the maintenance differentiation agent in the maintenance medium: 10 μg/mL insulin and 1 μM rosiglitazone.
The beneficial effects of the invention are as follows:
the intramuscular fat cells obtained by the buffalo fetus obtained by the method have higher activity and capacity of adipogenic differentiation.
The method for inhibiting the intramuscular fat cells of the buffalo fetuses by contact does not need to adopt a method that the density is close to 100 percent and the contact is inhibited for 2 days, and the better induction effect can be achieved when the density reaches 80 percent.
Drawings
Fig. 1: morphological observation of buffalo intramuscular adipocytes. FIG. 1A shows purified buffalo intramuscular fat cells after 2 days of culture; FIG. 1B shows the purified buffalo intramuscular fat cells after 6 days of culture.
Fig. 2: induced culture of buffalo intramuscular adipocytes for 0, 2,4, 6, 8, 10 days of the cell conditions of example 1. In the figure, "Day" means "Day".
Fig. 3: detection of expression levels of adipogenic marker Gene fatty acid binding protein 4 (FATTY ACID-binding protein, FABP 4), peroxisome proliferator-activated receptor gamma (peroxisome proliferators-ACTIVATED RECEPTORS gamma, PPARgamma or PPARG), and enhancer binding protein alpha (CCAAT/enhancer binding proteins alpha, C/EBP alpha). The "d" on the abscissa in the figure represents "day".
Fig. 4: oil red O staining patterns of uninduced cells and cells after induction for 10 days in example 1. The left side of FIG. 4 shows the induced cells, and the right side of FIG. 4 shows the cells after 10 days of induction.
Fig. 5: the 80% density direct induction of buffalo intramuscular adipocytes of example 1 and the 100% density contact inhibition of example 2 induced conditions after 2 days. In the figure, "day" means "day".
Fig. 6: absorbance of uninduced cells and 10 day post-induction cell oil red O staining in example 1. The "d" on the abscissa in the figure represents "day".
Fig. 7: triglyceride levels in cells after 0, 2, 6, 10 days of induction in example 1. "day" on the abscissa in the figure indicates "day".
Fig. 8: western blot was used to detect intracellular levels of PPARG protein during different induction periods. In the figure, "Day" means "Day".
Detailed Description
The following detailed description of the present invention is provided to facilitate understanding of the technical solution of the present invention, but is not intended to limit the scope of the present invention.
Experimental reagent: type I collagenase (Solarbio), high sugar medium (Hyclone), fetal Bovine Serum (FBS) (holly), green/streptomycin (Hyclone), trypsin (Hyclone); bovine insulin (Sigma), dexamethasone (Sigma), 3-isobutyl-1-methylxanthine (Sigma), rosiglitazone (Sigma), oil red O powder (Sigma), triglyceride assay kit (priril), quantitative enzyme, reverse transcriptase, protein Marker (Vazyme), phosphate buffered saline (Phosphate buffer saline, PBS), beta-actin rat anti-purchased from Biyunnan, PPARG rabbit anti-purchased from Abisxin, RIPA tissue/cell lysate and PMSF purchased from Soxhoba.
The 75% alcohol in the examples represents 75% by volume of ethanol in the alcohol.
The double antibody is a green/streptomycin solution, and is a mixed solution prepared from 100U/mL penicillin and 0.1mg/mL streptomycin.
Phosphate buffer solution of 1 or 3 times of blue/streptomycin is prepared by adding 1% or 3% of blue/streptomycin by volume percent into phosphate buffer solution.
The phosphate buffer solution preheated by 1%, 2% and 3% of cyan/streptomycin is the phosphate buffer solution preheated by 1%, 2% and 3% of cyan/streptomycin by volume percentage.
0.2% Collagenase I refers to: 10mLDMEM, the mass of collagenase I is 0.02g.
The DMEM medium containing 20% of fetal calf serum and 1% of diab is the DMEM medium containing 20% of fetal calf serum and 1% of diab by volume.
The induction medium is prepared by adding an induction differentiation agent into DMEM medium containing 20% of fetal calf serum and 1% of diabody.
The maintenance medium is a DMEM medium containing 20% fetal bovine serum and 1% diabody, and a maintenance differentiation agent is added.
Oil red O mother liquor: 0.25g of oil red O powder was dissolved in 50mL of isopropanol.
By 4% paraformaldehyde is meant that the paraformaldehyde solution comprises 4% by volume paraformaldehyde.
60% Isopropyl alcohol means that the isopropyl alcohol solution contains 60% by volume of isopropyl alcohol.
Example 1
A method for separating, culturing and adipogenic inducing differentiation of buffalo fetal intramuscular fat cells comprises the following steps:
Step 1: and (3) disinfection: the epidermis of buffalo embryo cattle is firstly washed by phosphate buffer salt solution of 3 times of green/streptomycin, the epidermis is removed, and the longest muscle of the back of buffalo embryo cattle is taken. Under the aseptic condition, the longest muscle tissue of the back of the cattle is soaked in the phosphate buffer salt solution which contains 1 percent, 2 percent and 3 percent of the blue/chain mycin for 2 minutes in sequence, is soaked in the alcohol of 75 percent for 30 seconds, and is soaked in the phosphate buffer salt solution which contains 3 percent, 2 percent and 1 percent of the blue/chain mycin for 2 minutes in sequence.
Step 2: segmentation: the sterilized longissimus muscle tissue blocks of buffalo embryo and cattle back are divided into 1-2 mm 3 by scissors.
Step 3: digestion: transferring 1-2 mm 3 tissue blocks into a 15mL centrifuge tube by using a 1mL pipetting gun, adding 0.2% collagenase I which is 2 times the volume of the tissue blocks, and digesting for 90-120 min on a constant temperature shaking table at 37 ℃ until flocculence appears.
Step 4: and (3) screening: digestion was terminated by adding the digested tissue to DMEM medium containing 20% fetal bovine serum and 1% diabody in an equivalent volume to 0.2% collagenase I.
Step 5: and (3) centrifuging: the cells which have stopped digestion are transferred through a 200 mesh cell sieve to a 50mL centrifuge tube and centrifuged at 1500rpm for 10min, and the supernatant is discarded to give a cell pellet.
Step 6: purifying: the centrifuged cells were resuspended in DMEM medium containing 20% fetal bovine serum and 1% diabody and purified by differential adherence.
The differential adherence method comprises the following steps: culturing the resuspended cells in an incubator at 37 ℃ and 5% CO 2 for 1h, discarding the culture medium containing non-adherent cells, washing 2 times with 1 times of blue/streptomycin phosphate buffer solution, and then adding DMEM culture medium containing 20% fetal calf serum and 1% diabody into the cells for continuous culture; the phosphate buffer solution of 1 times of blue/streptomycin is phosphate buffer solution added with 1% of blue/streptomycin.
Step 7: culturing: purified cells were cultured in an incubator at 37℃with 5% CO 2, and the DMEM medium containing 20% fetal bovine serum and 1% diabody was changed every 2 days. After the cell density reaches about 80%, the induction culture medium is replaced, the maintenance culture medium is replaced after the induction is carried out for 2 days, and then the maintenance culture medium is replaced every two days for 6-8 days.
The components of the induced differentiation agent in the induction medium are as follows: 0.5mM 3-isobutyl-1-methylxanthine, 1. Mu.M dexamethasone, 10. Mu.g/mL insulin and 1. Mu.M rosiglitazone; the components of the maintenance differentiation agent in the maintenance medium: 10 μg/mL insulin and 1 μM rosiglitazone.
Example 2
A method for separating, culturing and adipogenic inducing differentiation of buffalo fetal intramuscular fat cells comprises the following steps:
Step 1: and (3) disinfection: the epidermis of buffalo embryo cattle is firstly washed by phosphate buffer salt solution of 3 times of green/streptomycin, the epidermis is removed, and the longest muscle of the back of buffalo embryo cattle is taken. Under aseptic condition, the longest muscle tissue of the back of the cattle is soaked in phosphate buffer salt solution which contains 1%, 2% and 3% of blue/chain mycin for 2min, is soaked in 75% of alcohol for 30s, and is soaked in PBS which contains 3%, 2% and 1% of blue/chain mycin for 2min.
Step 2: segmentation: the sterilized longus muscle tissue blocks of the cattle back are divided into 1-2 mm 3 by scissors.
Step 3: digestion: transferring 1-2 mm 3 tissue blocks into a 15mL centrifuge tube by using a 1mL pipetting gun, adding 0.2% collagenase I which is 2 times the volume of the tissue blocks, and digesting for 90-120 min (until flocculence appears) on a constant temperature shaking table at 37 ℃.
Step 4: and (3) screening: digestion was terminated by adding the digested tissue to DMEM medium containing 20% fetal bovine serum and 1% diabody in an equivalent volume to 0.2% collagenase I.
Step 5: and (3) centrifuging: the cells which have stopped digestion are transferred through a 200 mesh cell sieve to a 50mL centrifuge tube and centrifuged at 1500rpm for 10min, and the supernatant is discarded to give a cell pellet.
Step 6: purifying: the centrifuged cells were resuspended in DMEM medium containing 20% fetal bovine serum and 1% diabody and purified by differential adherence.
The differential adherence method comprises the following steps: culturing the resuspended cells in an incubator at 37 ℃ and 5% CO 2 for 1h, discarding the culture medium containing non-adherent cells, washing 2 times with 1 times of blue/streptomycin phosphate buffer solution, and then adding DMEM culture medium containing 20% fetal calf serum and 1% diabody into the cells for continuous culture; the phosphate buffer solution of 1 times of blue/streptomycin is phosphate buffer solution added with 1% of blue/streptomycin.
Step 7: culturing: purified cells were cultured in an incubator at 37℃with 5% CO 2, and the DMEM medium containing 20% fetal bovine serum and 1% diabody was changed every 2 days. After the cell density reaches 100% and the contact inhibition is carried out for 2 days, the induction culture medium is replaced, the maintenance culture medium is replaced after the induction is carried out for 2 days, and then the maintenance culture medium is replaced every two days for 6-8 days.
The components of the induced differentiation agent in the induction medium are as follows: 0.5mM 3-isobutyl-1-methylxanthine, 1. Mu.M dexamethasone, 10. Mu.g/mL insulin and 1. Mu.M rosiglitazone; the components of the maintenance differentiation agent in the maintenance medium: 10 μg/mL insulin and 1 μM rosiglitazone.
1. Morphological observation of intramuscular fat cells of buffalo fetuses
After the cells centrifuged in step 6 of example 1 were resuspended in DMEM medium containing 20% fetal bovine serum and 1% diabody, the cells were pellet-shaped and in suspension.
After the purified irregular triangle and fusiform cells obtained in the step 6 of the example 1 are continuously cultured for 2 days in an incubator with 5% CO 2 at 37 ℃, intramuscular fat cells start to stretch, and form fibers when the shuttles appear, as shown in fig. 1A, the cells are vigorous, the cell clone density can reach 100% after continuous culture for 4 days, as shown in fig. 1B, and the cells can be passaged.
(1) Lipid-forming induced differentiation of buffalo fetal intramuscular adipocytes
As can be seen from fig. 2, the cells after induction for 2 days in example 1 were rounded, and the adipogenesis thereof was more and more apparent as the induction time of the intramuscular adipocytes was increased.
Total RNA of cells (cells induced for 0,2, 4, 6, 8, 10 days) was extracted by TRIzol method, RNA was inverted into cDNA by using a Reprandial reverse transcription kit, qRT-PCR experiments were performed by using a quantitative enzyme of Reprandial, and primers used for qRT-PCR are shown in Table 1. Data processing and analysis was then performed using GRAPHPAD PRISM f.
As shown in FIG. 3, the expression level of adipogenic marker genes (FABP 4, PPARG and C/EBP. Alpha.) was significantly increased by inducing differentiation of intramuscular adipocytes of buffalo fetuses.
TABLE 1qRT-PCR primers
2. Detection of cell induction effect by oil red O
Cells to be stained with oil red O (cells induced for 0 day, 10 days in examples 1, 2) were discarded, washed 3 times with PBS, fixed for 30min with 4% paraformaldehyde, prepared with oil red O working solution (PBS: oil red O mother liquor (volume ratio) =2:3), left to stand for 20min, filtered through a 0.25 μm filter membrane, discarded with 4% paraformaldehyde, washed with 60% isopropanol, discarded with 60% isopropanol, added with oil red O working solution, stained for 30min, discarded with oil red O working solution, washed 3 times with PBS, and photographed with a microscope.
As a result, as shown in FIG. 4, lipid droplets were stained red with oil red O, and cells after 10 days of induction in example 1 were much more than lipid droplets in uninduced cells.
FIG. 5 illustrates that 80% density direct induction of buffalo intramuscular fat cells of example 1 resulted in mature macrofat droplets, while 100% density contact inhibition of example 2 was not good after adipogenic induction for 2 days.
Measurement of stained oil red O stained cells by enzyme-labeling instrument:
The cells of example 1, which had been stained with oil red O, were washed with 100% isopropanol, added to a 96-well plate using a pipette at 100. Mu.L per well, and the OD was measured at a wavelength of 510nm using an ELISA reader. As a result, as shown in FIG. 6, the absorbance of the cells induced for 10 days in example 1 was significantly higher than that of the uninduced cells at 510 nm.
3. Induction of triglyceride determination in cells
The medium in the cells induced for 0, 2,6, 10 days in example 1 was discarded, washed 2 times with PBS, the cells were collected by digestion with pancreatin, centrifugation and then lysed, and 100. Mu.L of lysate was added to the cells of each well, and the mixture was allowed to stand at room temperature for 10min. Transferring proper amount of lysate into a 1.5mL centrifuge tube for triglyceride measurement, and storing the rest lysate in BCA method protein quantification kit (Biyun day) at-20deg.C. The lysate used for triglyceride measurement was heated at 70℃for 10min, and flocculent precipitate may appear when the tissue amount was large. Centrifugation at 2000rpm for 5min at room temperature, the supernatant was used for enzymatic identification.
As shown in fig. 7, the induced differentiation of buffalo fetal intramuscular adipocytes significantly increased intracellular triglyceride levels.
4. Western blot detection of intracellular PPARG protein levels at different induction periods
Buffalo fetal intramuscular adipocytes induced for 0, 2, 6, 10 days after induction of example 1 were collected. And extracting buffalo fetus intramuscular fat cell proteins in different induction periods by using RIPA tissue/cell lysate and PMSF. Running electrophoresis by using 10% SDS-PAGE, transferring film, shaking table sealing at room temperature by 5% skimmed milk powder for 1h, incubating overnight at the temperature of the primary antibody at 4 ℃, shaking table incubating for 1h at the temperature of the secondary antibody, and developing color. The results are shown in fig. 8, which induced 2 days higher levels of PPARG protein than other periods. This means that when culturing in step 7, the operation of changing the induction medium and changing the maintenance medium after the induction for 2 days after the cell density reaches about 80%, and that excellent induction effect can be obtained for the buffalo fetal intramuscular fat cells.
The above-described embodiments are merely preferred embodiments of the present invention and are not intended to limit the scope of the present invention, so that all equivalent changes or modifications of the structure, characteristics and principles described in the claims should be included in the scope of the present invention.
Claims (8)
1. A method for separating, culturing and adipogenic inducing and differentiating intramuscular fat cells of buffalo fetuses, which is characterized by comprising the following steps:
Step 1: and (3) disinfection: firstly, cleaning the epidermis of the buffalo embryo cattle, removing the epidermis, taking the longus muscle of the cattle dorsum of the buffalo embryo, and sterilizing the longus muscle tissue of the cattle dorsum under the aseptic condition;
step 2: segmentation: dividing the longest muscle tissue blocks of the beef dorsum of the disinfected buffalo embryo;
step 3: digestion: adding 0.2% collagenase I into the segmented tissue blocks for digestion;
step 4: and (3) screening: adding complete culture medium to the digested tissue to terminate digestion;
Step 5: and (3) centrifuging: centrifuging the cells which terminate digestion, and discarding the supernatant to obtain a cell pellet;
Step 6: purifying: re-suspending the centrifuged cells in a complete culture medium, and purifying the cells by a differential adherence method;
Step 7: culturing: culturing the purified cells in an incubator with 5% CO 2 at 37 ℃ for 2 days, and changing the complete culture medium once; after the cell density reaches 80%, changing the induction culture medium, inducing for 2 days, changing the maintenance culture medium again, and changing the maintenance culture medium every 2 days;
The induction culture medium is a complete culture medium added with an induction differentiation agent, and the induction differentiation agent in the induction culture medium comprises the following components: 0.5 mM 3-isobutyl-1-methylxanthine, 1. Mu.M dexamethasone, 10. Mu.g/mL insulin and 1. Mu.M rosiglitazone;
The maintenance medium is a complete medium added with a maintenance differentiation agent, and the maintenance differentiation agent in the maintenance medium comprises the following components: 10. mu.g/mL insulin and 1. Mu.M rosiglitazone.
2. The method for isolated culture and adipogenic induced differentiation of intramuscular fat cells of buffalo fetus according to claim 1, wherein,
In the step 1, the buffalo embryo bovine epidermis is cleaned by adopting 3 times of blue/streptomycin phosphate buffer salt solution, wherein the 3 times of blue/streptomycin phosphate buffer salt solution is a mixed solution prepared by adding 3% of blue/streptomycin into phosphate buffer salt solution, and the blue/streptomycin solution is 100U/mL penicillin and 0.1mg/mL streptomycin.
3. The method for isolated culture and adipogenic induced differentiation of intramuscular fat cells of buffalo fetus according to claim 1, wherein,
In the step 1, the cattle dorsum longissimus tissues are soaked for 2 min sequentially by using a phosphate buffer salt solution containing 1%, 2% and 3% of green/streptomycin preheating, soaked for 30s by using 75% of alcohol, and soaked for 2 min sequentially by using a phosphate buffer salt solution containing 3%, 2% and 1% of green/streptomycin preheating.
4. The method for isolated culture and adipogenic induced differentiation of intramuscular fat cells of buffalo fetus according to claim 1, wherein,
The complete medium is DMEM medium containing 20% fetal bovine serum and 1% diabody.
5. The method for isolated culture and adipogenic induced differentiation of intramuscular fat cells of buffalo fetus according to claim 1, wherein,
Step 2 is to divide the sterilized longus muscle tissue blocks of the cattle back into 1-2 mm 3.
6. The method for isolated culture and adipogenic induced differentiation of intramuscular fat cells of buffalo fetus according to claim 1, wherein,
Step 3 is to add collagenase I with the volume of 0.2% which is 2 times of the volume of the tissue blocks into the segmented tissue blocks, and digest the tissue blocks on a constant temperature shaking table with the temperature of 37 ℃ to 90 min-120 min.
7. The method for isolated culture and adipogenic induced differentiation of intramuscular fat cells of buffalo fetus according to claim 6, wherein,
In step 4, the volume of complete medium added was the same as the volume of 0.2% collagenase I added in step 3.
8. The method for isolated culture and adipogenic induced differentiation of intramuscular fat cells of buffalo fetus according to claim 1, wherein,
The differential adherence method in the step 6 is as follows: culturing cells in an incubator at 37deg.C and 5% CO 2 for 1 h, discarding culture medium containing non-adherent cells, washing with 1 times of blue/streptomycin phosphate buffer solution for 2 times, and adding DMEM culture medium containing 20% foetal calf serum and 1% double antibody into the cells;
The phosphate buffer solution of 1 times of blue/streptomycin is phosphate buffer solution added with 1% of blue/streptomycin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210697735.9A CN114990057B (en) | 2022-06-20 | 2022-06-20 | Method for separating and culturing intramuscular fat cells of buffalo fetuses and inducing differentiation into fat |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210697735.9A CN114990057B (en) | 2022-06-20 | 2022-06-20 | Method for separating and culturing intramuscular fat cells of buffalo fetuses and inducing differentiation into fat |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114990057A CN114990057A (en) | 2022-09-02 |
CN114990057B true CN114990057B (en) | 2024-04-26 |
Family
ID=83034147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210697735.9A Active CN114990057B (en) | 2022-06-20 | 2022-06-20 | Method for separating and culturing intramuscular fat cells of buffalo fetuses and inducing differentiation into fat |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114990057B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007125859A1 (en) * | 2006-04-24 | 2007-11-08 | Primary Cell Co., Ltd. | Method for induction of the differentiation of visceral fat cell |
CN107858327A (en) * | 2017-12-20 | 2018-03-30 | 河南农业大学 | Separation, culture and the method for inducing differentiation of the intramuscular Preadipocyte In Vitro of one breeder |
CN113717932A (en) * | 2021-09-16 | 2021-11-30 | 四川农业大学 | Primary isolation culture and induced differentiation method for intramuscular precursor adipocytes of adult yaks |
-
2022
- 2022-06-20 CN CN202210697735.9A patent/CN114990057B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007125859A1 (en) * | 2006-04-24 | 2007-11-08 | Primary Cell Co., Ltd. | Method for induction of the differentiation of visceral fat cell |
CN107858327A (en) * | 2017-12-20 | 2018-03-30 | 河南农业大学 | Separation, culture and the method for inducing differentiation of the intramuscular Preadipocyte In Vitro of one breeder |
CN113717932A (en) * | 2021-09-16 | 2021-11-30 | 四川农业大学 | Primary isolation culture and induced differentiation method for intramuscular precursor adipocytes of adult yaks |
Non-Patent Citations (5)
Title |
---|
S. M. Waters.Effect of level of eicosapentaenoic acid on the transcriptional regulation of Δ-9 desaturase using a novel in vitro bovine intramuscular adipocyte cell culture model.Animal.2009,第3卷(第5期),全文. * |
TNC 基因在牛肌肉发育和前体脂肪细胞诱导 分化过程中的表达研究;祁艳霞;云南农业大学学报(自然科学);20190315;第34卷(第2期);全文 * |
刘斌.《细胞培养》.世界图书出版公司,2018,第57页. * |
刘真真.水牛脂肪干细胞生物学特性及表观遗传修饰检测的初步研究.《中国优秀硕士学位论文全文数据库农业科技辑》.2018,全文. * |
水牛肌内脂肪沉积关键基因的筛选及相关功能研究;冯雪;中国优秀硕士学位论文全文数据库农业科技辑;20210915;全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN114990057A (en) | 2022-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2205724B1 (en) | Method for isolating and culturing adult stem cells derived from human amniotic epithelium | |
JP2012120545A (en) | Method for refining cell | |
WO2010040262A1 (en) | Methods for isolating animal embryonic mesenchymal stem cells and extracting secretion substance thereof | |
Castagnola et al. | Type X collagen synthesis by cultured chondrocytes derived from the permanent cartilaginous region of chick embryo sternum | |
CN106591224B (en) | Method for separating and purifying high-purity chicken precursor intramuscular fat cells and constructing coculture system of high-purity chicken precursor intramuscular fat cells and muscle satellite cells | |
CN106854638B (en) | Method for inducing mesenchymal stem cells to differentiate into islet-like cells | |
CN112143708B (en) | Umbilical cord mesenchymal stem cells, stem cell essence factor and application thereof in aspect of resisting skin aging | |
US20130059378A1 (en) | Human epidermis-derived mesenchymal stem cell-like pluripotent cells and preparation method thereof | |
JP5388297B2 (en) | Adipo cluster | |
AU2002308446A1 (en) | A method of purification cells | |
Kitani et al. | Isolation and characterization of mouse neural precursor cells in primary culture | |
CN116034987A (en) | Tissue and cell preservation solution, cell separation method and application thereof | |
CN114874979A (en) | Separation and purification method of donkey skeletal muscle satellite cells | |
WO2022140847A1 (en) | Methods and processes for culturing cells | |
CN114990057B (en) | Method for separating and culturing intramuscular fat cells of buffalo fetuses and inducing differentiation into fat | |
CN112029717B (en) | Serum-free in vitro domestication culture of human mesenchymal stem cells | |
CN115125192A (en) | Bone marrow supernatant and application thereof in cell culture | |
JP4915722B2 (en) | Separation method of kidney stem / progenitor cells | |
Watanabe | CHANGES IN THE CAPACITY FOR CLONAL GROWTH AND DIFFERENTIATION IN VITRO OF THE VERTEBRAL CARTILAGE CELLS WITH EMBRYONIC DEVELOPMENT II. VITALIZING EFFECT OF CONDITIONED MEDIUM ON THE CELLS OF YOUNGER EMBRYOS | |
CN115386541B (en) | Construction method and application of pig FAPs immortalized cells | |
Claycomb et al. | Culture and characterization of fetal human atrial and ventricular cardiac muscle cells | |
CN111849884B (en) | Induction method for directional differentiation of human placental amniotic membrane stem cells into hepatocytes | |
EP4245846A1 (en) | Early mesenchymal stem cells with reduced aging and preserved stem cell ability, and culturing method therefor | |
CN117625528B (en) | Preparation method of mesenchymal stem cells | |
CN117625527A (en) | Method for separating, identifying and adipogenic differentiating mammalian fat precursor cells, composition and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |